Mice lacking the peroxisome proliferator-activated receptor alpha gene present reduced number of dopamine neurons in the substantia nigra without altering motor behavior or dopamine neuron decline over life

Neuroscience

Volumn 186, Issue , 2011, Pages 161-169

  Gonzalez Aparicio, R ^a   Flores, J A ^a   Tasset, I ^b   Tunez, I ^b   Fernandez Espejo, E ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

^b UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

Aging; Dopamine; Oxidation; PPAR ; Substantia nigra

Indexed keywords

ANTIOXIDANT; INTERLEUKIN 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL NUCLEUS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DORSAL STRIATUM; DOWN REGULATION; GENE SILENCING; LOCOMOTION; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA; WILD TYPE;

ANIMALS; ANTIOXIDANTS; DOPAMINE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MOTOR ACTIVITY; NERVOUS SYSTEM MALFORMATIONS; NEURONS; PPAR ALPHA; SUBSTANTIA NIGRA;

EID: 79957993491     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.03.062     Document Type: Article

References (48)

1. Abdolzade-Bavil A., Hayes S., Goretzki L., Kröger M., Anders J., Hendriks R. Convenient and versatile subcellular extraction procedure, that facilitates classical protein expression profiling and functional protein analysis. Proteomics 2004, 4(5):1397-1405.
2. Aguirre J.A., Cintra A., Hillion J., Narváez J.A., Jansson A., Antonelli T., et al. A stereological study on the neuroprotective actions of acute modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse. Neurosci Lett 1999, 275(3):215-218.
3. Akiyama T.E., Nicol C.J., Fievet C., Staels B., Ward J.M., Auwerx J., et al. Peroxisome proliferator-activated receptor-alpha regulates lipid homeostasis, but is not associated with obesity: studies with congenic mouse lines. J Biol Chem 2001, 276:39088-39093.
4. Aoyama T., Peters J.M., Iritani N., Nakajima T., Furihata K., Hashimoto T., et al. Altered constitutive expression of fatty acid-metabolizing enzymes in micelacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J Biol Chem 1998, 273(10):5678-5684.
5. Bełtowski J., Wójcicka G., Mydlarczyk M., Jamroz A. The effect of peroxisome proliferator-activated receptors alpha (PPARalpha) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON 1) activity. J Physiol Pharmacol 2002, 53(3):463-475.
6. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
7. Calne D.B., Langston J.M. Ethiology of Parkinson's disease. Lancet 1983, 2:1457-1459.
8. Chen X.R., Besson V.C., Palmier B., Garcia Y., Plotkine M., Marchand-Leroux C. Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. J Neurotrauma 2007, 24(7):1119-1131.
9. Cullingford T.E., Bhakoo K., Peuchen S., Dolphin C.T., Patel R., Clark J.B. Distribution of mRNAs encoding the peroxisome proliferator-activated receptor alpha, beta, and gamma and the retinoid X receptor alpha, beta, and gamma in rat central nervous system. J Neurochem 1998, 70:1366-1375.
10. Cuzzocrea S., Mazzon E., Di Paola R., Peli A., Bonato A., Britti D., et al. The role of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha) in the regulation of acute inflammation. J Leukoc Biol 2006, 79(5):999-1010.
11. Delerive P., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001, 169:453-459.
12. Deplanque D., Gelé P., Pétrault O., Six I., Furman C., Bouly M., et al. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 2003, 23(15):6264-6271.
13. Diab A., Hussain R.Z., Lovett-Racke A.E., Chavis J.A., Drew P.D., Racke M.K. Ligands for the peroxisome proliferator-activated receptor-gamma and the retinoid X receptor exert additive anti-inflammatory effects on experimental autoimmune encephalomyelitis. J Neuroimmunol 2004, 148:116-126.
14. Drew P.D., Xu J., Storer P.D., Chavis J.A., Racke M.K. Peroxisome proliferator-activated receptor agonist regulation of glial activation: relevance to CNS inflammatory disorders. Neurochem Internat 2006, 49(2):183-189.
15. Felten D.L., Felten S.Y., Steece-Collier K., Date I., Clemens J.A. Age-related decline in the dopaminergic nigrostriatal system: the oxidative hypothesis and protective strategies. Ann Neurol 1992, 32:S133-S166.
16. Fernandez-Espejo E. Pathogenesis of Parkinson's disease: prospects of neuroprotective and restorative therapies. Mol Neurobiol 2004, 29:15-30.
17. Fernandez-Espejo E. Pathogenesis of oxidative stress and the destructive cycle in the substantia nigra in Parkinson's disease. Cortico-subcortical dynamics in Parkinson's disease 2009, 261-272. Humana Press, New York. K.Y. Tseng (Ed.).
18. Fukuda A., Osawa T., Hitomi K., Uchida K. 4-Hydroxy-2-nonenal cytotoxicity in renal proximal tubular cells: protein modification and redox alteration. Arch Biochem Biophys 1996, 333:419-426.
19. Galan-Rodriguez B., Suárez J., Gonzalez-Aparicio R., Bermudez-Silva F.J., Maldonado R., Robledo P., et al. Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons. Neuropharmacology 2009, 56:653-664.
20. Good P.F., Hsu A., Werner P., Perl D.P., Olanow C.W. Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol 1998, 57(4):338-342.
21. Goya K., Sumitani S., Xu X., Kitamura T., Yamamoto H., Kurebayashi S., et al. Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2004, 24(4):658-663.
22. Guellich A., Damy T., Lecarpentier Y., Conti M., Claes V., Samuel J.L., et al. Role of oxidative stress in cardiac dysfunction of PPARalpha-/-mice. Am J Physiol Heart Circ Physiol 2007, 293(1):H93-H102.
23. Gundersen H.J., Bagger P., Bendtsen T.F., Evans S.M., Korbo L., Marcussen N., et al. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 1988, 96:857-881.
24. Kainu T., Wikstrom A.C., Gustafsson J.A., Pelto-Huikko M. Localization of the peroxisome proliferator-activated receptor in the brain. Neuroreport 1994, 5:2481-2485.
25. Kono K., Kamijo Y., Hora K., Takahashi K., Higuchi M., Kiyosawa K., et al. PPAR{alpha} attenuates the proinflammatory response in activated mesangial cells. Am J Physiol Renal Physiol 2009, 296(2):F328-F336.
26. Kreisler A., Gelé P., Wiart J.F., Lhermitte M., Destée A., Bordet R. Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not. Brain Res 2007, 1135(1):77-84.
27. Lagares A., Avendaño C. An efficient method to estimate cell number and volume in multiple dorsal root ganglia. Acta Stereol 1999, 18:185-195.
28. Lleo A., Galea E., Sastre M. Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases. Cell Mol Life Sci 2007, 64:1403-1418.
29. McGeer P.L., Itagaki S., Akiyama H., McGeer E.G. Comparison of neuronal loss in Parkinson's disease and aging. Parkinsonism and aging 1989, 25-34. Raven, New York. D.B. Calne, G. Comi, D. Crippa, R. Horowski, M. Trabucchi (Eds.).
30. Melis M., Pillolla G., Luchicchi A., Montoni A.L., Yasar S., Goldberg S.R., Pistis M. Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. J Neurosci 2008, 28:13985-13994.
31. Moreno S., Farioli-Vecchioli S., Cerù M.P. Immunolocalization of peroxisome proliferators-activated receptor and retinoid X receptor in the adult rat CNS. Neuroscience 2004, 123:131-145.
32. Paradisis P.M., Campbell I.L., Barnum S.R. Elevated complement C5a receptor expression on neurons and glia in astrocyte-targeted interleukin-3 transgenic mice. Glia 1998, 24(3):338-345.
33. Paxinos G., Franklin K.B.J. The mouse brain in stereotaxic coordinates 2001, Academic Press, San Diego.
34. Peters J.M., Hennuyer N., Staels B., Fruchart J.C., Fievet C., Gonzalez F.J., et al. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem 1997, 272(43):27307-27312.
35. Petroske E., Meredith G.E., Callen S., Totterdell S., Lau Y.S. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 2001, 106:589-601.
36. Poynter M.E., Daynes R.A. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J Biol Chem 1998, 273:32833-32841.
37. Racke M.K., Gocke A.R., Muir M., Diab A., Drew P.D., Lovett-Racke A.E. Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis. J Nutr 2006, 136(3):700-703.
38. Ren L., Lubrich B., Biber K., Gebicke-Haerter P.J. Differential expression of inflammatory mediators in rat microglia cultured from different brain regions. Brain Res Mol Brain Res 1999, 65(2):198-205.
39. Reymond M.A., Sanchez J.C., Hughes G.J., Günther K., Riese J., Tortola S., et al. Standardized characterization of gene expression in human colorectal epithelium by two-dimensional electrophoresis. Electrophoresis 1997, 18(15):2842-2848.
40. Scherman D., Desnos C., Darchen F., Pollak P., Javoy-Agid F., Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol 1989, 26:551-557.
41. Schmidt A., Vogel R., Holloway M.K., Rutledge S.J., Friedman O., Yang Z., et al. Transcription control and neuronal differentiation by agents that activate the LXR nuclear receptor family. Mol Cell End 1999, 155:51-60.
42. Schulz J.B., Matthews R.T., Beal M.F. Role of nitric oxide in neurodegenerative diseases. Curr Opin Neurol 1995, 8(6):480-486.
43. Schwarting R.K.W., Huston J.P. The unilateral 6-hydroxydopamine lesion model in behavioral brain research: analysis of functional deficits, recovery and treatments. Prog Neurobiol 1996, 50:275-331.
44. Sterio D.C. The unbiased estimation of number and sizes of arbitrary particles using the desector. J Microsc 1984, 134:127-136.
45. Stokes A.H., Hastings T.G., Vrana K.E. Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 1999, 55(6):659-665.
46. Tatton W.G., Greenwood C.E., Verrier M.C., Holland D.P., Kwan M.M., Biddle F.E. Different rates of age-related loss for four murine monoaminergic neuronal populations. Neurobiol Aging 1991, 12:543-556.
47. Xu J., Chavis J.A., Racke M.K., Drew P.D. Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J Neuroimmunol 2006, 176(1-2):95-105.
48. Xu J., Racke M.K., Drew P.D. Peroxisome proliferator-activated receptor-alpha agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis. J Neurochem 2007, 103(5):1801-1810.